Efficacy of gefitinib combined with bevacizumab versus gefitinib in advanced EGFR L858R NSCLC.

被引：0
|
作者：
Zhao, Xinmin
Wu, Xianghua
Wang, Huijie
Yu, Hui
Sun, Si
Feng, Yu
Wang, Jialei
机构：
[1] Fudan Univ, Shanghai Canc Ctr, Dept Med Oncol, Shanghai, Peoples R China
[2] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai, Peoples R China
[3] Fudan Univ, Shanghai Canc Ctr, Dept Oncol, Shanghai Med Coll, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.e21185
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21185
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Efficacy and safety of gefitinib plus bevacizumab versus gefitinib monotherapy in patients with EGFR L858R mutant non-small cell lung cancer (NSCLC): A randomized, open-controlled, single-center trial
    Wang, J.
    Zhao, X.
    Xiong, K.
    Liu, C.
    Wu, X.
    Wang, H.
    Yu, H.
    Sun, S.
    Hu, Z.
    Lin, Y.
    Zhang, Y.
    Yu, B.
    Wu, Z.
    [J]. ANNALS OF ONCOLOGY, 2023, 34
  • [2] Acquired gefitinib-resistant mutation of EGFR in a chemonaive lung adenocarcinoma harboring gefitinib-sensitive mutation L858R
    Gow, CH
    Shih, JY
    Chang, YL
    Yu, CJ
    [J]. PLOS MEDICINE, 2005, 2 (09): : 924 - 925
  • [3] FLAIR: Phase II Study of Osimertinib plus Bevacizumab versus Osimertinib in Advanced NSCLC Patients with EGFR L858R Mutation
    Zhou, Q.
    Xu, C.
    Chen, H.
    Tu, H.
    Wang, B.
    Yan, H.
    Zhang, X.
    Yang, J.
    Zhong, W.
    Liu, S.
    Wu, Y.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S613 - S613
  • [4] EGFR copy number and gefitinib efficacy in advanced NSCLC
    [J]. Nature Clinical Practice Oncology, 2005, 2 (7): : 328 - 328
  • [5] Optimizing Treatment Outcomes for L858R EGFR+ NSCLC
    Monsen, J.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S732 - S732
  • [6] Efficacy and correlation with predictive markers of gefitinib in pretreated Chinese patients with advanced NSCLC.
    Zhang, XT
    Li, LY
    Chang, XY
    Mu, XL
    Wang, SL
    Wang, MZ
    Zhong, W
    Zhang, L
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 680S - 680S
  • [7] Gefitinib as first-line treatment for patients with NSCLC with activating EGFR mutationin exons 19 (Del19) or 21 (L858R) in the Czech Republic
    Skrickova, Jana
    Bortlicek, Zbynek
    Hejduk, Karel
    Pesek, Milos
    Kolek, Vitezslav
    Koubkova, Leona
    Roubec, Jaromir
    Havel, Libor
    Salajka, Frantisek
    Tomiskova, Marcela
    Satankova, Monika
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2015, 46
  • [8] Landscape of osimertinib resistant mutations between the two common subtypes of EGFR 19del or L858R in NSCLC.
    Zhang, Yan
    Zhao, Jun
    Guo, Renhua
    Lin, Gen
    Liu, Li
    Zhu, Chenchen
    Liang, Naixin
    Yang, Huaxia
    Wang, Wen xian
    Dai, Pingping
    Guan, Yan-Fang
    Yang, Ling
    Yi, Xin
    Xia, Xuefeng
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [9] Elucidating the genomic and transcriptomic landscape of L858R vs ex19del EGFR-mutated NSCLC.
    Saw, Stephanie Pei Li
    Pang, Mengyuan
    Yeo, Jia Chi
    Alvarez, Jacob
    Sim, Ngak Leng
    Ng, Win Pin
    Lai, Gillianne
    Tan, Aaron C.
    Jain, Amit
    Tan, Wan Ling
    Kanesvaran, Ravindran
    Ng, Quan Sing
    Lim, Darren Wan-Teck
    Ang, Mei-Kim
    Lim, Tony Kiat Hon
    Ong, Boon-Hean
    Chua, Kevin Lee Min
    Tan, Daniel Shao-Weng
    Skanderup, Anders
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [10] Low Plasma Concentration Of Gefitinib In Patients With EGFR Exon 21 L858r Point Mutations Shorten Progression Free Survival
    Okuda, Y.
    Satou, K.
    Miura, H.
    Sudou, K.
    Asano, M.
    Takeda, M.
    Sano, M.
    Watanabe, H.
    Shioya, T.
    Itou, H.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2015, 191
12345